Man Group
FENC icon

Man Group’s Fennec Pharmaceuticals FENC Stock Holding History

Man Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,630
Closed -$126K – 1895
2022
Q4 		$131K Buy
+13,630
New +$121K ﹤0.01% 1859

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Man Group's FENC Position: Q1 2023 in Review

Man Group sold out of Fennec Pharmaceuticals (FENC) in Q1 2023, closing a stake of 13,630 shares — an estimated $126K sold.

Man Group first reported a position in FENC in Q4 2022 and held it in 1 quarter. The position peaked at $131K in Q4 2022. 53 funds tracked by Wall St. Rank hold FENC as of Q1 2023.

  • Man Group reported no remaining Fennec Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 13,630 Fennec Pharmaceuticals shares in Q1 2023, an estimated $126K.
  • Man Group first reported a position in Fennec Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Man Group's Fennec Pharmaceuticals position peaked at $131K in Q4 2022.
  • 53 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.